人胰岛素类似物与人胰岛素减低糖化血红蛋白水平的比较研究

Comparative study on the level of glycosylated hemoglobin in patients with diabetes treated with actrapid monotard analog or actrapid monotard

目的探讨人胰岛素类似物与人胰岛素减低糖化血红蛋白（HbA1c）水平的差异。方法随机抽取120例2型糖尿病患者，按住院号奇偶数分为人胰岛素类似物组和人胰岛素组，每组60例，比较两组在患病结局、血糖控制、HbA1c之间的差异。结果人胰岛素类似物组治疗良好率（83．3％，50／60）与人胰岛素组治疗良好率（86．7％，52／60）比较差异无统计学意义（P〉0．05）。治疗前两组空腹血糖和餐后2h血糖比较差异无统计学意义（P〉0．05），治疗2周后两组比较差异有统计学意义（P〈0．05）；两组内治疗前与治疗2周后空腹血糖和餐后2h血糖比较差异均有统计学意义（P〈0．05）。治疗前两组HbA1c比较差异无统计学意义（P〉0．05），治疗3个月后两组比较差异有统计学意义（P〈0．05）；两组内治疗前与治疗3个月后HbA1c比较差异均有统计学意义（P〈0．05）。结论人胰岛素类似物与人胰岛素在控制糖尿病患者血糖和HbA1c方面效果均较好，但人胰岛素类似物优于人胰岛素。

Objective To compare the level ofglycosylated hemoglobin （HbAlc）in patients with diabetes treated with aetrapid monotard analog or actrapid monotard. Methods One hundred and twenty patients with type 2 diabetes were divided into aetrapid monotard analog group and aetrapid monotard group with 60 cases in each by admission number. Fasting blood glucose （FBG）, 2-hour postprandial blood glucose （2hPBG）, HbAlc were obtained and analyzed. Results The overall cure rate were similar between aetrapid monotard analog group and actrapid monotard group （.83.3% ,50/60 vs. 86.7%,52/60, P〉 0.05）. There was no significant difference in FBG, 2hPBG before treatment between two groups （P 〉 O.05）,but there was significant difference at 2 weeks after treatment between two groups （P 〈 0.05 ） . There was no significant difference in HbAIe before treatment between two groups （P 〉 0.05 ）, but there was significant difference at 3 months after treatment between two groups （P 〈 0.05 ） . FBG, 2hPBG, HbA1c after treatment were improved compared with before treatment in two groups （P 〈 0.05 ）. Conclusion Actrapid monotard analogprovides better blood glucose control compare with actrapid monotard while providing the convenience of injecting immediately before meals.